Understanding the pharmacokinetics of tulathromycin: a pulmonary perspective
Article first published online: 30 SEP 2013
© 2013 John Wiley & Sons Ltd
Journal of Veterinary Pharmacology and Therapeutics
Volume 37, Issue 3, pages 211–221, June 2014
How to Cite
Understanding the pharmacokinetics of tulathromycin: a pulmonary perspective. J. vet. Pharmacol. Therap. 37, 211–221., , .
- Issue published online: 7 MAY 2014
- Article first published online: 30 SEP 2013
- Manuscript Accepted: 28 JUL 2013
- Manuscript Received: 23 JUL 2012
Tulathromycin is approved in the United States for the treatment of respiratory disease in bovine and swine, infectious bovine keratoconjunctivitis associated with Moraxella bovis, and interdigital necrobacillosis in bovine. This macrolide highly concentrates in lung tissue and persists in the intra-airway compartment for a long time after a single administration. It also accumulates in inflammatory cells, including neutrophils and macrophages. This article reviews pharmacokinetic information about tulathromycin in different veterinary species with particular emphasis on the respiratory system.